Amcinonide A 8 1 Amcinonide (Triamcinolone acetate cyclopentanoide) ATC: D07AC11; H02AB Use: topical glucocorticoid RN: 51022-69-6 MF: C,,H,,FO, MW: 502.58 EINECS: 256-915-2 LDs,: >5 @g (M, p.0.); >2 glkg (R, p.0.) CN: (1 1 P, 16a)-21-(acety1oxy)- 16,17-[cyclopentylidenebis(oxy)]-9-fluoro-ll-hydroxypregna-1,4-diene-3,20- dione triarncinolone cyclopentanone triarncinolone cyclopentanonide (I) Reference(s): GB 1 442 925 (American Cyanamid; USA-prior. 17.8.1973). ocetonhydride DOS 2 437 847 (American Cyanamid; applT 6.8.1974; USA-prior. 17.8.1973). BE 818 929 (American Cyanamid; appl. 16.8.1974; USA-prior. 17.8.1973). US 4 158 055 (American Cyanamid; 12.6.1979; USA-prior. 6.6.1975). Arncinonide Formulation(s): cream 0.1 %; lotion 0.1 %; ointment 0.1 % Trade Narne(s): D: Amciderm (HermaVMerck; Penticort Neomycine USA: Cyclocort (Fujisawa; 1979) 1985) (Wyeth-Leder1e)-comb. F: Penticort (Wyeth-Lederle; I: Amcinil (Crosara) 1980) J: Visderm (Lederle; 1982) Amezinium metilsulfate ATC: COlCAOO Use: selective noradrenergic antihypotensive RN: 30578-37-1 MF: C,,H,,N,O . CH,O,S MW: 313.33 EINECS: 250-248-0 LD,,: 28 mgkg (M, i.v.); 1330 mglkg (M, p.0.); 24 mgkg (R, i.v.); 1410 mgkg (R, p.0.); 60 mgkg (dog, i.v.); 100 mglkg (dog, p.0.) CN: 4-amino-6-methoxy-1-phenylpyridazinium methyl sulfate 82 A Amfebutamone chloride RN: 51410-15-2 MF: CllH,,CIN,O MW: 237.69 2-butyne- rnucachloric 1.4-dial acid hydrazine C I I NH2 sulfate pyridozinone (I) Reference(s): Reicheneder, F. et al.: Arsneim Forsch. (ARZNAD) 31 (11), 1.529 (1981). DE 1 912 941 (BASF; appl. 14.3.1969). DOS 2 139 687 (BASF; appl. 7.8.1971). DOS 2 21 1 662 (BASF; appl. 10.3.1972). DOS 3 1 14 496 (BASF; appl. 10.4.1981). EP 63 267 (BASF; appl. 31.3.1982; D-prior. 10.4.1981). 4-amino-5- 4-om~no-1- precursors: DE 2 100 685 (BASF; appl. 8.1.1971). Arneziniurn rnetilsulfote Formulation(s): amp. 5 mg; tabl. 10 mg chlaro-1- phenyl-6(1 H)- phenyl-6(1H)- pyridazinone pyridozinone Trade Nanze(s): D: Regulton (Knoll) Supratonin (Griinenthal) Amfebutamone (Bupropion) ATC: N06AE Use: antidepressant RN: 34911-55-2 MF: C,,H,,ClNO MW: 239.75 LD,,: 544 mg/kg (M, p.0.) CN: (+)- 1-(3-chloropheny1)-2-[(I ,1 -dimethylethyl)amino]-1 -propanone hydrochloride RN: 31677-93-7 MF: C,,H,,ClNO . HCl MW: 276.21 EINECS: 250-759-9 LD,,,: 230 mgkg (M, i.p.); 575 mgkg (M, p.0.); 210 mg/kg (R, i.p.); 600 mglkg (R, p.0.) I Amfenac sodium A 83 3-chloro- ethylmagnesium 5'-chloro- benzonitrile bromide propiophenone tert-butyl- amine I Amfebutamone Rejerence(s): DOS 2 059 61 8 (Wellcome; appl. 3.12.1970; GB-prior. 4.12.1969). DOS 2 064 934 (Wellcome; appl. 3.12.1970; GB-prior. 4.12.1 969). CA 977 778 (Wellcome; appl. 15.1 1.1970). I Formulation(s): s. r. tabl. 100 mg, 150 mg (as hydrochloride); tabl. 75 mg, 100 mg Trade Name(s): USA: Wellbutrin (Glaxo Wellcome) Zyban (Glaxo Wellcome) Amfenac sodium RN: 61941-56-8 MF: C,,H,,NNaO, MW: 277.26 LD,,: 550 mgkg (M, i.v.); 615 mgkg (M, p.0.); 277 mgkg (R, i.v.1; 31 1 mglkg (R, p.0.) CN: 2-amino-3-benzoylbenzeneacetic acid monosodium salt monohydrate RN: 61618-27-7 MF: C,,H,,NNaO, . H20 MW: 295.27 amfenac RN: 51579-82-9 MF: C15H,,N0, MW: 255.27 LD,,: 615 mgkg (M, p.0.); 31 1 mglkg (R, p.0.) 1. HZ. Pd-C. NoOH 2. NoN02. HCI ATC: MOlAB Use: non-steroidal anti-inflammatory, analgesic 3. SKI2 W 2. sodium nitrite phenyl- 3. tin(ll) chloride NH2 ocetone N -2 84 A Amfepramone Amfenoc sodium u Reference(s): DOS 2 324 768 (Robins; appl. 16.5.1973; USA-prior. 17.5.1972). US 4 045 576 (Robins; USA-prior. 17.5.1972) Welstead, W.J. et a].: J. Med. hem. (JMCMAR) 22, 1074 (1979). 1 -aminoindolin-2-one: Lora Tamayo, M. et al.: Org. Prep. Proced. Int. (OPPIAK) 8,45 (1976) Trade Name(s): J: Fenazox (Meiji Seika) Amfepramone (Diethy lpropion) ATC: A08AA03 Use: appetite depressant RN: 90-84-6 MF: C13H19N0 MW: 205.30 EINECS: 202-019-1 LD,,: 160 mglkg (M, p.0.); >400 mgkg (R, p.0.) CN: 2-(diethylamino)- l -phenyl- 1-propanone hydrochloride RN: 134-80-5 MF: C,3H19N0 . HC1 MW: 241.76 EINECS: 205-156-5 LD,,,: 50 mglkg (M, i.v.); 385 mglkg (M, p.0.); 400 mglkg (R, p.0.) propiophenone a-bromo- propiophenone I Amfepromone ( Reference(s): US 3 001 910 (Temmler-Werke; 26.9.1961; D-prior. 16.4.1958). Amidephrine mesilate A 85 Formulafion(s): cps. 25 mg, 75 mg; s. r. cps. 375 mg; s. r. tabl. 75 mg; tabl. 25 rng, 75 mg Trade Name(s): D: Regenon retard (Tcmmler) GB: Tenuate (Synomed) F: Moderatan (ThCranol- Deglaude) PrCfamone (Dexo) Tenuate-Dospan (Marion I: Merrell) Amidephrine mesilate (Amidefrine mesilate) Apisate (Wyeth)-comb.; USA: Tenuate (Merrcll-National); wfm wfm Tenuate (Merrell); wfm Tepanil (Riker); wfm Tcnuate Dospan (Merrell); wfrn Linea Valeas (Valeas) Tenuate Dospan (Lepctit) ATC: R03A Use: rhinological therapcutic, vasoconstrictor, sympathomimetic RN: 1421-68-7 MF: CloH,6N203S. CH403S MW: 340.42 LD,,,: 190 mgkg (M, i.v.); 2284 mglkg (M, p.0.); 13 mgkg (R, p.0); 1400 gkg (dog, Lv.) CN: ' (+)-N-[3-[l -hydroxy-2-(methylamino)ethyl]phenyl]mcthanesulfonamide monomethanesulfonate amidephrine RN: 37571-84-9 MF: C,,Hl,N,03S MW: 244.32 methonesulfonyl 3-orninooceto- chloride phenone 3-methylsulfonylornino- acetophenone (I) a-brorno-3-methyl- a-bcnzylrnethylomino-3- sulfanylominoocetophenone rnethylsulfonylorninoacetophenone (II) I Amidephrine mesilote J FR-M 3 027 (Mead Johnson; appl. 23.1.1963; USA-prior. 24.1.1962, 14.12.1962). For-mulation(s): sol. 0.1 % Trade Name(s): GB: Dricol (Brislol); wfm 86 A Amidotrizoic acid Amidgtrizoic acid (Diatrizoic acid) ATC: V08AAO1 Use: X-ray contrast medium RN: 117-96-4 MF: CllHyI,N204 MW: 613.92 EINECS: 204-223-6 LD,,,: 8900 mglkg (M, i.v.); >12.3 glkg (R, i.v.) CN: 3,5-bis(acety1amino)-2,4,6-triiodobenzoic acid monosodium salt RN: 737-3 1-5 MF: CllH,I,N2Na04 MW: 635.90 EINECS: 212-004-1 LD,,,: 14 glkg (M, i.v.); >7 gkg (M,R, p.0.); 11.4 glkg (R, i.v.); 13.2 g/kg (dog, i.v.) meglumine salt RN: 8064-12-8 MF: C,,H,13N,Na04 . CllHyI,N,O,~ C,H,,NO, MW: 1445.03 LD,,: 11.5 gkg (M, i.v.); 29.2 mglkg (R, i.v.) Hz. Pd-C .6:", KICIZ - potossiumb 02N H2N dichloro- reH2 H2N I iodate 3.5-dinitrobenzoic acid 3,5-diaminobenzoic acid 3,5-diamino-2.4,6- triiadobenzaic acid (I) ocetic onhydride I Amidolrizaic acid I 0 0 H2S04 I + H3CKoKCH3 d Reference (s): Larsen, A.A. et al.: J. Am. Chem. Soc. (JACSAT) 78, 3210 (1956). GB 748 319 (Schering AG; appl. 1954; D-prior. 1953). GB 782 3 13 (Mallinckrodt; appl. 1955; USA-prior. 1954). US 3 076 024 (Sterling Drug; 29.1 .l963; appl. 19.2.1954). DE 1 260 477 (Schering AG; appl. 1954; USA-prior. 1953). COOH H3C 1 N H IH salts with amino acids: DAS 2 261 584 (Dr. F. Kohler Chemie; appl. 15.12.1972). Formulation(s): amp. 0.65 glml; inj. sol. 31 %-73 % Tradv Name(s): D: Angiografin (Schering) Gastrografin (Schering) Peritrast (Kohler; as lysine salt) Urografin (Schering) Urovison (Schering) F: Angiografine (Schering) Gastrografine (Schering) RadiosClectan (Schering) GB: Gastrografin (Schering Chemicals); wfrn Hypaque (Winthrop); wfrn Urografin (Schering Chemicals); wfrn I: Gastrografin (Schering)- comb. Selectografin (Schering)- comb. J: Urografin (Schering- Nichidoku Yakuhin) USA: Cardiografin (Squibb); wfrn Cystografin (Squibb); wfrn Gastrografin (Squibb); wfrn Hypaque-Cysto (Winthrop); wfrn Hypaque-Diu (Winthrop); wfrn Amifostine A 87 Hypaque Sodium Reno-M-30 (Squibb); wfm Renovist (Squibb); wfm (Winthrop); wfm Reno-M-60 (Squibb); wfm Sinografin (Squibb)-comb. Meglumine Diatrizoate Reno-M-DIP (Squibb); with adipiodon; wfm (Squibb); wfm wfm Amifos tine ATC: ~03~~05 (Eth~ophos; Gammaphos; NSC-296961; WR 272 1) Use: mucolytic agent, radioprotector, reduction of cisplatin induced renal toxicity RN: 20537-88-6 MF: CsHlsN203PS MW: 214.23 LD,,,: 557 mg/kg (M, i.v.); 842 mg/kg (M, p.0.); 826 mglkg (R, p.0.) CN: 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate (ester) bromide dihydrobromide I I H H2" HzN-N-Br " 2HBr tr~sod~um th~ophosphote dodecohydrate 2-(3-ominopropylamino)ethyl Reference(s): DD 289 448 (Amt fiir Atomsicherheit; appl. 29.7.1982; DDR-prior. 29.7.1982). DD 289 449 (Amt fiir Atomsicherheit; appl. 29.7.1983; DDR-prior. 29.7.1983). H Amifastine composition having improved stability: WO 9 403 179 (US Bioscience; appl. 30.7.1993; USA-prior. 31.7.1992). preparation of monohydrate: JP54 046 722 (Yamanouchi; appl. 12.4.1979; J-prior. 21.9.1977). preparation via 2-(3-aminopropy1amino)ethyI bromide: SU 751 030 (Kortun; 30.6.1981; SU-prior. 4.1.1979). use forprotection during radio- and chemotherapy: US 5 298 499 (Res. Triangle Inst.; appl. 5.7.1991; USA-prior. 5.7.1991). WO 8 907 942 (US Bioscience; appl. 21.2.1989; USA-prior. 23.2.1988). US 5 167 947 (Southwest Res. Inst.; appl. 26.10:1989; USA-prior. 26.10.1989). US 3 892 824 (Southern Res. Inst.; appl. 16.12.1988; USA-prior. 16.12.1988). use for reducing side effects with azidothymidine: WO 9 014 007 (US Bioscience; appl. 9.5.1990; USA-prior. 24.5.1989) use for prevention of cytostatic alopecia: DE 3 509 071 (ASTA-Werke; appl. 14.3.1985; D-prior. 29.3.1984). Formulation(s): amp. 500 mg; vial 500 mg dry substance for inj. Trade Name(s): D: Ethyol (Essex Pharma; GB: Ethyol (Schering-Plough) 1995) 8 8 A Amikacin Amikacin ATC: D06AX12; JOIGB06; SOIAA21 Use: aminoglycoside antibiotic RN: 37517-28-5 MF: C22H43NJ013 MW: 585.61 EINECS: 253-538-5 LD5,: 280 mgkg (M, i.v.); >6 glkg (M, p.0.) CN: (S)-O-3-amino-3-deoxy-~-~-glucopyranosyl-(1+6)-0-[6-amino-6-deoxy-a-u-glucopyranosyl-(l~4)]- N1-(4-amino-2-hydroxy- l -0xobuty1)-2-deoxy-D-streptamine sulfate (12) RN: 39831-55-5 MF: C,H,3NS0,3. 2H2S0, MW: 781.76 EINECS: 254-648-6 LD,,: 18 1 mg/kg (M, i.v.); >I0679 gkg (M, p.0.); 234 mglkg (R, i.v.); >4 glkg (R, p.0.); 383 rnglkg (dog, i.v.) kanarnycin A (4. v.) NH~ ~~-(benz~lax~carbon~I)kanarn~cin A (I) I Arnikacin LC-)- y-benzylaxycarbonylornino- a-hydroxybutyric acid succinirnido ester GB 1 401 221 (Bristol Myers; appl. 13.7.1972; USA-prior. 13.7.1971). DE 2 234 3 15 (Bristol-Myers; appl. 12.7.1972; USA-prior. 27.1.1972. 13.7.1971). US 3 781 268 (Bristol-Myers; 25.12.1973; prior. 27.1.1972, 13.7.1971). Kawaguchi, H. et al.: J. Antibiot. (JANTAJ) 25, 695 (1972). Amiloride A 89 alternative syntheses: NL 7 401 517 (Bristol-Myers; appl. 4.2.1974; USA-prior. 7.2.1973). NL 7 414 668 (Bristol-Myers; appl. 11.11.1974; USA-prior. 14.11.1973, 23.5.1974). US 3 974 137 (Bristol-Myers; 10.8.1976; prior. 23.5.1974). DOS 2 432 644 (Takeda; appl. 8.7.1974; J-prior. 12.7.1973). DOS 2 716 533 (Pfizer; appl. 14.4.1977; GB-prior. 14.4.1976). DOS 2 818 822 (Bristol-Myers; appl. 28.4.1978; USA-prior. 28.4.1977, 20.3.1978). DOS 2 818 992 (Bristol-Myers; appl. 28.4.1978; USA-prior. 28.4.1977; 20.3.1978). disulfate pentahydrate: FR 2 308 373 (Bristol-Myers; appl. 22.3.1976; USA-prior. 23.4.1975). review: Kawaguchi, H.; Hiroshi: Drug Action Drug Resist. Bact. (DADRBY) 2,45 (1975). Formulation(s): cream 2.5 %, 5 %; eye drops 0.3 %, 0.5 %; gel 5.5; vial 100 mg/2 ml, 250 mgl2 ml, 500 mg/2 ml Trade Name(s): D: Biklin (Bristol-Myers Squibb; 1976) F: Amiklin (Bristol-Myers Squibb) GB: Amikin (Bristol-Myers Squibb; 1976) I: Amicasil (Biotekfarma) Bb-k8 (Bristol; 1978) Chemacin (CT) Pierami (Pierrel; 1980) Likacin (Lisapharma; Sifamic (SIFI) 1981) J: Amikacin Sulfate (Banyu) Lukadin (San Carlo) Biklin (Banyu-Bristol- Migracin (SmithKline Myers Squibb) Beecham) USA:. Amilun (BMS; 1976) Mikavir (Salus Research; 1986) Amiloride ATC: C03DBOl Use: diuretic, antihypertonic RN: 2609-46-3 MF: C,HuClN70 MW: 229.63 EINECS: 220-024-7 CN: 3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide monohydrochloride RN: 2016-88-8 MF: C6HuC1N70 . HC1 MW: 266.09 EINECS: 217-958-2 YHO + CHO glyoxal 5.6-diaminouracil lumazine 3-aminopyrazine- 2-carboxylic acid (1) methanol methyl 3-omino- methyl 6-chloro- pyrazine-2-carboxylote 3.5-diaminopyrazine- 2-carboxylate (U) 90 A Amineptine guonidine I Arniloride I Reference(s): DE 1 470 053 (Mercle & Co.; appl. 28.10.1963; USA-prior. 30.10.1962). US 3 313 813 (Merck & Co.; 11.4.1967; prior. 30.10.1962,7.10.1963). GB 1 066 855 (Merck & Co.; appl. 24.10.1963; USA-prior. 30.10.1962,7.10.1963). Bicking, J.B. et al.: J. Med. Chem. (JMCMAR) 8,638 (1965). Cragoe, E.J. et al.: J. Med. Chem. (JMCMAR) 10, 66 (1967). improved method for 5,6-diaminouracil: DOS 2 831 037 (Lonza; appl. 14.7.1978; CH-prior. 20.7.1977). combination with etacrynic acid: US 3 781 430 (Merck & Co.; 25.12.1973; prior. 30.10.1962,7.10.1963,7.2.1966, 18.2.1969, 21.12.1971). Fomulation(s): tabl. 2.5 mg, 5 mg, 10 mg in comb. with hydrochlorothiazide (as hydrochloride) Trade Name(s): D: Amiduret (Trommsdorff; 1985)-comb. Diaphal (Pierre Fabre Pharma)-comb. Diursan (TAD)-comb. Esmalorid (Merck)-comb. Moducrin (MSD; 1978)- comb. Moduretik, -mite (Du Pont Pharma; 1973)-comb. Rhefluin, -mite (Kytta- Siegfried)-comb. F: LogirCne (Pharmacia & Upjohn SA)-comb. Modamide (Merck Sharp & Dohme; 1973) Moducren (Merck Sharp & Dohme-Chibret; 1979)- comb. Modurktic (Merck Sharp & Dohme; 1973)-comb. GB: Amilco (Baker Norton; 1983)-comb. with hydrochlorothiazole Burinex A (Leo)-comb. I: FruCo (Baker Norton)- comb. USA: Frumil (RhGne-Poulenc Rorer; 1983)-comb. Kalten (Zeneca; 1985)- comb. Lasoride (Hoechst; 1987)- comb. Moducren (Morson; 198 1)- comb. Moduret-25 (Du Pont; 1984)-comb. Moduretic (Du Pont; 1970) Navispare (Novartis)-comb. Moduretic (Merck Sharp & Dohme; 1975)-comb. Midamor (Merck Sharp & Dohme; 1981) Moduretic (Merck Sharp & Dohme; 1981)-comb. Amineptine ATC: N06AA19 Use: psychoanaleptic, CNS stimulant RN: 57574-09-1 MF: C22H27N02 MW: 337.46 EINECS: 260-818-0 LD,,,: 1 15 mglkg (M, i.p.) CN: 7-[(10,1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptoic acid hydrochloride RN: 30272-08-3 MF: C2,HZ7NO, . HCI MW: 373.92 EINECS: 250-107-3 LD,,: 405 mglkg (M, p.0.) . CN: (S)-O-3-amino-3-deoxy- ~-~ -glucopyranosyl-(1+6 )-0 -[ 6-amino-6-deoxy-a-u-glucopyranosyl-(l~4) ]- N 1-( 4-amino-2-hydroxy- l -0 xobuty1 )-2 -deoxy-D-streptamine sulfate (12) RN: 398 3 1-5 5-5 MF:. 298 499 (Res. Triangle Inst.; appl. 5.7. 199 1; USA-prior. 5.7. 199 1). WO 8 90 7 94 2 (US Bioscience; appl. 21.2. 198 9; USA-prior. 23.2. 198 8). US 5 167 94 7 (Southwest Res. Inst.; appl. 26.10: 198 9;. 2 39. 75 LD,,: 544 mg/kg (M, p.0.) CN: (+ )- 1-( 3-chloropheny1 )-2 -[ (I ,1 -dimethylethyl)amino ]-1 -propanone hydrochloride RN: 3167 7 -9 3-7 MF: C,,H,,ClNO . HCl MW: 276.21 EINECS: 25 0-7 5 9- 9